Phase 4 COPD Trial, Recruiting NCT03105843 Sponsor: Dr. Diane Lougheed Condition: COPD
Back to Copd

Phase 4 COPD Trial, Recruiting

NCT03105843
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 65 years old who have been diagnosed with cough-variant asthma (CVA), meaning they have had a persistent cough for 8 weeks or more as their main symptom, tested positive on a specific breathing test called a methacholine challenge, and have a history of their cough improving with asthma treatments such as inhaled steroids or bronchodilators.
  • Adults between 18 and 65 years old who have had a persistent cough for 8 weeks or more as their main symptom but tested negative on the methacholine challenge breathing test.
  • Adults between 18 and 65 years old with no history of asthma or long-term persistent cough (this group may serve as a comparison group — confirm with trial site).

Who may not be able to join:

  • People who have had a worsening of their condition in the past 4 weeks that required a change in medication, a visit to the emergency department, or a hospital stay.
  • People who are unable to perform a standard breathing test called spirometry.
  • People who have a medical reason they cannot safely undergo methacholine challenge testing (confirm with trial site for specific conditions this covers).
  • People who have a significant smoking history of more than 10 pack-years (roughly, smoking one pack of cigarettes per day for more than 10 years, or the equivalent amount over a different time period).

Note: Having previously used inhaled or oral corticosteroid (steroid) medications does not prevent someone from being considered — the trial will record and review medication use as part of the study.


Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: M. Diane Lougheed, MD, MSc, Department of Medicine, Queen's University

Phone: 613-548-2348

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Dr. Diane Lougheed
Registry
ClinicalTrials.gov
Start date
1 March 2022
Est. completion
1 June 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Mid expiratory flows

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov